Merck Group
Tracked across 28 events · 1555 articles · First seen Mar 09, 2018 · Last active Aug 23, 2026
Live sentiment trends, attention charts, and prominence tracking available on the
Ergen Dashboard
Business
Impact: Merck Group is acquiring Bio-Techne — Bio-Techne Diagnostics Corporation to expand its life sciences business, reduce reliance on marketed drugs, and strengthen its position in high-growth areas like multi-omics and cell and gene therapy. This acquisition is its largest in over a decade and is expected to be immediately accretive to sales growth and EBITDA pre margin.
Jun 25, 2026 · 21 articles
Regulatory
Impact: Merck Group received FDA Breakthrough Therapy designation for its investigational drug enpatoran, a key regulatory milestone that could expedite development and approval, potentially boosting its immunology pipeline and market position.
Jul 08, 2026 · 6 articles
Business
Merck reported second-quarter revenue of $16.61 billion, up 5% year-over-year and above analyst expectations, driven by strong sales of its cancer drug Pembrolizumab. Pembrolizumab sales rose 5% to $8.37 billion, including $463 million from the…
Impact: Merck is the central company, reporting strong Q2 results and raising revenue guidance. Its stock rose 0.6% in early trading, reflecting positive market reception.
Aug 04, 2026 · 6 articles
Tech
Moderna and Merck & Co. announced on August 19, 2026, that their personalized mRNA cancer vaccine, Intismeran, combined with Merck's immunotherapy drug Pembrolizumab, met its primary and secondary goals in a Phase 3 trial for…
Impact: Merck co-developed the vaccine and provided Pembrolizumab, the combination partner. Its shares rose about 10-12%, and the success helps Merck prepare for Pembrolizumab's patent expiration by expanding its cancer portfolio.
Aug 19, 2026 · 102 articles
Business
Impact: Merck Group>>> committed globally to Veeva Vault CRM as part of its digital initiatives, aiming to support consistent processes and data connectivity across functions.
May 27, 2026 · 6 articles
Accidents
The Democratic Republic of the Congo received its first shipment of more than 16,000 doses of the Ervebo Ebola vaccine on August 22, 2026, as the country battles its deadliest Ebola outbreak on record. The…
Impact: Merck Group is the developer of Ervebo, the only approved Ebola vaccine, which is being deployed in the DRC outbreak. Its role is central, and successful cross-protection could expand its market and reputation.
Aug 22, 2026 · 8 articles
Accidents
The Democratic Republic of the Congo is experiencing its deadliest Ebola outbreak on record, caused by the rare Bundibugyo ebolavirus. As of August 19, 2026, the outbreak has surpassed 5,000 confirmed cases and over 2,300…
Impact: Merck Group's Ervebo vaccine is being deployed in the outbreak response, potentially increasing sales. However, its efficacy against the Bundibugyo strain is unproven, and the trial outcome will be critical.
Aug 01, 2026 · 295 articles
Tech
Impact: Merck Group is listed among the top companies in the epigenetics market, suggesting its involvement and potential for growth within this expanding sector.
Jun 26, 2026 · 6 articles
Business
Impact: Merck Group is mentioned as a top company in the Air Quality Monitoring Systems Market, indicating its participation in a growing sector.
Jun 09, 2026 · 6 articles
Domestic
On August 10, 2026, President Donald Trump signed an executive order overhauling the U.S. childhood vaccine schedule. The order reduces the number of universally recommended vaccines from 18 to 11 diseases, recommends splitting the combined…
Impact: As a major MMR manufacturer, it faces potential regulatory and market changes. It stated no scientific evidence supports splitting the vaccine, and it may face pressure to develop separate shots.
Aug 10, 2026 · 235 articles
Domestic
President Donald Trump signed an executive order directing the United States — United States Department of Health and Human Services to split the combined measles, mumps, and rubella (MMR) vaccine into three separate shots, claiming…
Impact: Merck, the sole U.S. manufacturer of the MMR vaccine, stated it cannot produce separate shots for at least 10 years. The executive order could create regulatory and market uncertainty, though current sales are unaffected.
Aug 23, 2026 · 12 articles
Business
Impact: Affiliate Lamond Ventures co-led the round, reflecting Merck's strategic interest in genetic medicine.
Jul 07, 2026 · 6 articles
Accidents
The Democratic Republic of the Congo is experiencing its largest and fastest-growing Ebola outbreak on record, caused by the rare Bundibugyo virus for which there are no approved vaccines or treatments. The outbreak, declared on…
Impact: Manufacturer of RVSV-ZEBOV vaccine, which is being considered for cross-protection trials. Its vaccine could play a role in the response, benefiting its reputation.
Mar 09, 2018 · 543 articles
Tech
Impact: Merck Group executives are participating in the summit, with Anna Guenter delivering a keynote on AI-ready leadership.
Jun 18, 2026 · 7 articles
International
Impact: Announced plans to allow generic production of alimatravir, potentially expanding market access.
Jul 21, 2026 · 68 articles
Business
AstraZeneca announced on August 17, 2026, that it is discontinuing the Phase III EVOLVE-Lung02 trial of volrustomig plus chemotherapy in patients with metastatic non-small cell lung cancer (mNSCLC). The decision followed a recommendation from an…
Impact: Merck's Keytruda is the comparator in the trial, and the failure of volrustomig may reinforce the competitive position of Keytruda in lung cancer treatment.
Aug 17, 2026 · 20 articles
Business
Impact: Merck Group agreed to acquire Bio-Techne — Bio-Techne Diagnostics.
Jun 24, 2026 · 57 articles
Regulatory
Impact: Signed an MoU with Tata Group to support semiconductor ecosystem development in India.
Jun 30, 2026 · 69 articles
Business
Impact: Merck's Lipfendra, the first FDA-approved PCSK9 pill, represents a competitive threat to Scribe's injectable therapy. Merck's innovation underscores the competitive landscape.
Jul 06, 2026 · 25 articles
Business
Impact: Merck Group is a marquee customer of Sudeep Pharma, demonstrating its global presence.
Nov 19, 2025 · 8 articles
Business
Bicara Therapeutics, an AI-driven drug discovery company based in Chengdu, China, announced the successful closing of an oversubscribed Series A financing round, raising nearly $30 million. The round was co-led by Legend Holdings and Shanghai…
Impact: Merck Group is mentioned as a former employer of Beyang's team, lending expertise but not directly affected by the financing.
Jul 20, 2026 · 6 articles
Business
Impact: Merck Group is mentioned as a customer of Syngene, but the event has no direct impact on the company.
Jul 01, 2026 · 6 articles
Business
Cognizant (NASDAQ: CTSH) announced on August 16, 2026 that it will support the introduction and implementation of Benchling, the AI platform for R&D, at Kyowa Kirin's Tokyo Research Park and Fuji Research Park in Japan.…
Impact: Mentioned as a Benchling customer, indicating Benchling's credibility but not directly affected by this event.
Aug 17, 2026 · 6 articles
Business
Impact: Merck is a partner of Ascentage Pharma, but this event does not directly involve Merck.
Jul 26, 2026 · 6 articles
100
Merck Group announced trial resultsModerna Merck mRNA...
90
Merck Group reported revenueMerck beats Q2 on Keytruda strength
90
Merck Group partnered with ModernaModerna Merck mRNA...
90
Moderna partnered with Merck GroupModerna Merck mRNA...
83
Merck Group gained in tradingModerna Merck mRNA...
80
Merck Group raised revenue forecastMerck beats Q2 on Keytruda strength
80
Merck Group saw shares riseModerna Merck mRNA...
80
Merck Group plans to file for approval United States — Food and Drug AdministrationModerna Merck mRNA...
80
Merck Group developed vaccineEbola vaccine doses arrive in DRC
70
Merck Group cut earnings forecastMerck beats Q2 on Keytruda strength
70
Merck Group reported positive trial resultsModerna Merck mRNA...
70
World Health Organization planned trial of Merck vaccine Merck GroupDR Congo Ebola outbreak...
65
Merck Group plan to seek approvalModerna Merck mRNA...
60
Merck Group acquired Terns Pharmaceuticals Terns PharmaceuticalsMerck beats Q2 on Keytruda strength
60
Merck Group criticized vaccine splitting Donald TrumpTrump signs childhood...
60
Merck Group served as technical adviser Hilleman LaboratoriesDRC Ebola outbreak spreads...
60
Merck Group said cannot offer separate shotsTrump MMR Lethal Claim...
50
Merck Group stated supportTrump signs childhood...
40
Merck Group reported Gardasil salesMerck beats Q2 on Keytruda strength
40
Merck Group reported trial resultsMerck beats Q2 on Keytruda strength
30
Merck Group reported vaccine sales declineMerck beats Q2 on Keytruda strength
30
Merck Group reported animal health salesMerck beats Q2 on Keytruda strength
Moderna
co-developer
↔
Merck Group
Merck Group co-develops personalized mRNA cancer vaccines, including Intismeran,
Moderna
co-developer
↔
Merck Group
Moderna co-develops personalized mRNA cancer vaccines, including Intismeran, wit
+ 16 more relationships
View on Dashboard
ERGEN INTELLIGENCE
Track Merck Group live
Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.
Open Dashboard